Theralase Technologies (TSE:TLT) has released an update.
Theralase Technologies Inc. has announced promising preclinical results for their lead drug, Rutherrin®, showing significant efficacy in treating aggressive Non-Small Cell Lung Cancer in a mouse model. The drug, when activated by x-ray radiation, not only delayed tumor progression but also improved overall survival rates. These findings highlight Rutherrin®’s potential as a potent therapeutic option for lung cancer patients.
For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.
